Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BCRP Inhibitor on Adagrasib PK in Healthy Adults
NCT05924152Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adagrasib in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), sponsored by Mirati Therapeutics. Primary endpoints: Area Under the Curve (AUC) for Adagrasib at Day 8, Maximum Plasma Concentration (Cmax) for Adagrasib at Day 8 and 4 more. Started Jun 2023; status: completed.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05924152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924152.